Dec 09, 2013 05:47 PM

TCM Still Struggling to Find Cure for Its FDA Woes


(Beijing) – In November, the traditional Chinese medicine (TCM) Fuzheng Huayu Tablets passed the second phase of the U.S. Food and Drug Administration's (FDA) clinical testing.

Before this, only one TCM drug had cleared the second of the three phases needed for a medicine to hit the U.S. market. That was Compound Salvia Droplet Pills (CDSP), made by the Tasly Group of Tianjin. CDSP has still not passed FDA's third phase.

You've accessed an article available only to subscribers
Share this article
Open WeChat and scan the QR code